Belgian telcos: Digi launches new mobile offer at €7 per month with 30GB D'Ieteren: Belgium Sept car registration, Febiac cuts 2025 outlook to 405-410k new cars Dutch insurance: Achmea Sixth Steet JV done, new entrant for buyouts for ASR and NN Heijmans: I'm a steamroller baby Prosus: Just Eat Takeaway offer unconditional WDP: €22m investment in Romania
In this October update of our Dynamic Top Pick List we are removing VGP while adding Shurgard and Wolters Kluwer. Since its recent inclusion in our Dynamic Top Pick List in July-25, VGPs share rose by 10.6%. While we still believe there is significant upside to the share price, we don't see short term catalysts. In fact, the macro picture remains cloudy with the jury still out on the impact of tariffs and the erratic US policy shifts. Also, we are a bit concerned that competition in Western Eur...
Inventiva Appoints Andrew Obenshain as Chief Executive Officer Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Andrew Obenshain as Chief Executive Officer (“CEO”) of the Company. Mr. Obenshain will also join the Company’s Board of Directors. He succeeds Frédéric Cren, the Company’s co-founder...
Inventiva annonce la nomination d’Andrew Obenshain au poste de Directeur Général Daix (France), New York City (New York, Etats-Unis), le 1er octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce aujourd’hui la nomination d’Andrew Obenshain au poste de Directeur Général, à compter du 1er octobre 2025. M. Obenshain rejoindra également le Conseil d’administration de la Socié...
Over the past month, the EPRA BELUX index has underperformed (total return) the EPRA Developed Europe index by 3.2%, the STOXX50 by 5.4%, and the BEL20 by 3.6%. This underperformance relative to the EPRA Developed Europe Index can be attributed to the stronger performance of UK real estate compared to eurodenominated stocks, as UK equities led the recovery following a selloff in August. Additionally, the BELUX region had already posted strong year-to-date performance, which limited further upsid...
Public announcement in accordance with article 7:97, § 4/1 of the Belgian Code of Companies and Associations ("CCA") concerning the signing of a Pledge Agreement and a Letter of Consent and Release with Enodia Public announcement in accordance with article 7:97, § 4/1 of the Belgian Code of Companies and Associations ("CCA") concerning the signing of a Pledge Agreement and a Letter of Consent and Release with Enodia Signing of a Pledge Agreement and a Letter owf Consent and Release with Enodia in connection with the demerger of VOO On 2 June 2023, within the framework of the acquisition o...
Annonce publique conformément à l'article 7:97, § 4/1 du Code des sociétés et des associations (« CSA ») concernant la conclusion d’une Convention de Gage et d’une Lettre de Consentement et Mainlevée avec Enodia Annonce publique conformément à l'article 7:97, § 4/1 du Code des sociétés et des associations (« CSA ») concernant la conclusion d’une Convention de Gage et d’une Lettre de Consentement et Mainlevée avec Enodia Conclusion d’une Convention de Gage et d’une Lettre de Consentement et Mainlevée avec Enodia dans le cadre de la scission de VOO Le 2 juin 2023, dans le cadre de l'acquisi...
Openbare aankondiging in overeenstemming met artikel 7:97, § 4/1 van het Wetboek van vennootschappen en verenigingen ('WVV') over het afsluiten van een Pandovereenkomst en een Brief van instemming en opheffing met Enodia Openbare aankondiging in overeenstemming met artikel 7:97, § 4/1 van het Wetboek van vennootschappen en verenigingen ('WVV') over het afsluiten van een Pandovereenkomst en een Brief van instemming en opheffing met Enodia Afsluiting van een Pandovereenkomst en een Brief van instemming en opheffing met Enodia in het kader van de splitsing van VOO In het kader van de overnam...
Yesterday, UCB hosted an R&D call to highlight the phase 2a data for galvokimig from EADV 2025, which showed strong efficacy in atopic dermatitis (AD), with a 52.6% placebo-adjusted EASI75 response at week 12, outperforming other biologics in cross-trial comparison. The KOL highlighted galvokimig's potential for broad positioning across the AD treatment paradigm if the early data is replicated in later stage trials, especially as a monotherapy. We update our model for UCB, which brings us to a n...
Inventiva reported 1H25 results which hold no surprises, and confirmed its cash runway guidance to the end of 3Q26 and timeline for the topline readout from the phase 3 (NATiV3) trial of lanifibranor in MASH, which continues to be guided for 2H26. We believe this readout is de-risked by strong phase 2b data, and with oral dosing and clean safety (limited GI side effects), lanifibranor is well positioned to capture a meaningful share of the validated MASH commercial opportunity. Given relative un...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.